NCT00762996

Brief Summary

The objective of this study is to evaluate the clinical performance of two daily disposable contact lenses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2007

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2007

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

September 26, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 30, 2008

Completed
9 months until next milestone

Results Posted

Study results publicly available

June 23, 2009

Completed
Last Updated

June 19, 2018

Status Verified

May 1, 2015

Enrollment Period

2 months

First QC Date

September 26, 2008

Results QC Date

October 24, 2008

Last Update Submit

June 18, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Distance Visual Acuity

    logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values \> 0.00 indicate vision poorer than the ideal and values \<0.00 indicate vision greater than the ideal.

    1 week

Secondary Outcomes (1)

  • Lens Comfort

    1 week

Study Arms (4)

etafilcon A/etafilcon A

ACTIVE COMPARATOR

Period 1: etafilcon A, Period 2: etafilcon A

Device: etafilcon A

etafilcon A/omafilcon A

ACTIVE COMPARATOR

Period 1: etafilcon A, Period 2: omafilcon A

Device: etafilcon ADevice: omafilcon A

omafilcon A/etafilcon A

ACTIVE COMPARATOR

Period 1: omafilcon A, Period 2: etafilcon A

Device: etafilcon ADevice: omafilcon A

omafilcon A/omafilcon A

ACTIVE COMPARATOR

Period 1: omafilcon A, Period 2: omafilcon A

Device: omafilcon A

Interventions

contact lens

etafilcon A/etafilcon Aetafilcon A/omafilcon Aomafilcon A/etafilcon A

contact lens

etafilcon A/omafilcon Aomafilcon A/etafilcon Aomafilcon A/omafilcon A

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • They are of legal age (18 years) and capacity to volunteer.
  • They understand their rights as a research subject and are willing to sign a Statement of Informed Consent.
  • They are willing and able to follow the protocol.
  • They would be expected to attain at least 6.9 (20/30) in each eye with the study lenses.
  • They are able to wear contact lenses which have a back vertex power of -1.00 to -6.00DS.
  • They have a maximum of 1.00D of refractive astigmatism (i.e. \< 1.00 DC).
  • They have worn soft contact lenses within six months of starting the study.

You may not qualify if:

  • They have an ocular disorder which would normally contra-indicate contact lens wear.
  • They have a systemic disorder which would normally contra-indicate contact lens wear.
  • They are using any topical medication such as eye drops or ointment.
  • They are aphakic.
  • They have had corneal refractive surgery.
  • They have any corneal distortion resulting from previous hard or rigid lens wear or has keratoconus.
  • They are pregnant or lactating.
  • They have grade 2 or greater of any of the following ocular surface signs: corneal edema, corneal vascularization, corneal staining, tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear.
  • They have any infectious disease (e.g., hepatitis) or any immunosuppressive disease (e.g., HIV).
  • They have diabetes.
  • They are currently taking part in any other clinical study or research.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eurolens Research

Manchester, M60 1QD, United Kingdom

Location

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Results Point of Contact

Title
Kurt Moody, OD, FAAO
Organization
Vistakon

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 26, 2008

First Posted

September 30, 2008

Study Start

August 1, 2007

Primary Completion

October 1, 2007

Study Completion

October 1, 2007

Last Updated

June 19, 2018

Results First Posted

June 23, 2009

Record last verified: 2015-05

Locations